Halozyme Therapeutics, Inc.
HALO
$38.57
$0.110.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 25.62% | 34.46% | 58.71% | 49.50% | 48.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.62% | 34.46% | 58.71% | 49.50% | 48.91% |
| Cost of Revenue | 30.50% | 50.23% | 85.08% | 96.62% | 75.86% |
| Gross Profit | 23.41% | 27.77% | 48.50% | 33.84% | 39.23% |
| SG&A Expenses | 22.66% | 6.58% | 28.87% | 173.36% | 141.69% |
| Depreciation & Amortization | 59.39% | 50.44% | 491.20% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.29% | 34.49% | 81.45% | 156.20% | 121.43% |
| Operating Income | 18.36% | 34.42% | 35.61% | -11.06% | 4.90% |
| Income Before Tax | 39.94% | 36.49% | 24.24% | -23.10% | 0.16% |
| Income Tax Expenses | 42.63% | 194.56% | 142.31% | 132.20% | 130.34% |
| Earnings from Continuing Operations | 39.31% | 20.22% | -36.17% | -58.24% | -49.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.31% | 20.22% | -36.17% | -58.24% | -49.81% |
| EBIT | 18.36% | 34.42% | 35.61% | -11.06% | 4.90% |
| EBITDA | 24.80% | 37.13% | 57.15% | 10.13% | 21.19% |
| EPS Basic | 44.87% | 24.78% | -33.18% | -56.63% | -48.02% |
| Normalized Basic EPS | 27.94% | 43.42% | 38.87% | -12.02% | 5.25% |
| EPS Diluted | 45.50% | 26.84% | -32.14% | -56.00% | -47.06% |
| Normalized Diluted EPS | 29.05% | 44.43% | 40.21% | -11.35% | 6.93% |
| Average Basic Shares Outstanding | -3.59% | -3.32% | -3.45% | -3.13% | -2.72% |
| Average Diluted Shares Outstanding | -4.44% | -4.06% | -4.35% | -3.75% | -4.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
